Semax

Two-Molecule (here Three-Molecule) Calibration Block

Three chemically distinct molecules circulate in the Western community under “Semax” or “Semax-adjacent” labels. They are not interchangeable, and vendors actively blur the distinction.

Variant	Sequence / modification	Regulatory status	Community treatment
Semax (the GRLS-registered drug)	Met-Glu-His-Phe-Pro-Gly-Pro (free heptapeptide)	Russia-approved Rx since 1994 (JSC Peptogen 0.1% / 1% nasal drops); on Russian List of Vital & Essential Drugs since 7 Dec 2011	The “real thing” per the Russian-Rx camp; canonical intranasal protocol; what the FDA PCAC will discuss on 24 July 2026
N-Acetyl Semax	N-terminal acetylated heptapeptide	Not GRLS-registered; research-chemical / grey-market only	Vendor-claimed longer half-life; community uses with ~30–40% dose reduction vs Semax per Peptides.org guide; pharmacologically distinct
N-Acetyl Semax Amidate (“NASA”)	N-acetylated, C-terminal amidated	Not GRLS-registered; research-chemical / grey-market only	Vendor-claimed further extended duration and adamantyl-stabilised potency; LongeCity Ceretropic-era users report “less is more”; pharmacologically distinct from both above

Why this matters. CosmicNootropic and the Russian-Rx camp treat only the Peptogen 0.1%/1% formulation as legitimate Semax. Ceretropic-era LongeCity users and several current research-chemical vendors treat all three as members of a single “Semax family.” Peptides.org and Limitless Life publish dose-conversion tables. No head-to-head human PK/PD comparison exists; the Adan 1994 receptor-pharmacology data (PMID 7895772) characterises the heptapeptide only. Throughout this monograph, “Semax” refers to the Russian heptapeptide unless explicitly stated otherwise.

---

1. Identity

Field	Value	Source
INN / proposed INN	None assigned	[Academic secondary source — WHO MedNet, no record]
Common names	Semax, Семакс, ACTH(4-7)PGP, [Pro⁸,¹⁰,Gly⁹]ACTH(4-10)	Russian GRLS; Adan 1994 PMID 7895772
Sequence	H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (heptapeptide)	[Peer-reviewed preclinical — Potaman 1991 PMID 1652713]
Structural class	Synthetic ACTH(4-7) core extended by C-terminal Pro-Gly-Pro stabiliser; chemically identical to the [Pro⁸,¹⁰,Gly⁹]ACTH(4-10) of Adan 1994	[Peer-reviewed preclinical — Adan 1994]
CAS Registry No.	80714-61-0	[Academic secondary source — PubChem CID 11765873]
Molecular formula	C₃₇H₅₁N₉O₁₀S	[Academic secondary source — PubChem; DrugBank]
Average MW	813.92 Da (free base); ~887 Da (trifluoroacetate salt)	[Academic secondary source — PubChem]
Brand names	Семакс 0.1% nasal drops; Семакс 1% nasal drops (JSC Peptogen)	[Regulatory document — Russian GRLS]
DrugBank / BNF / USP	No monograph in any	[Academic secondary source — DrugBank, BNF, USP-NF; no entry]
Distinguished from	ACTH(4-10) endogenous melanocortin (rapidly cleaved); N-acetyl-Semax and N-acetyl-Semax-amidate (“Adamax”) — separate research analogues, not GRLS-registered	[Academic secondary source]

---

2. History and Development

The development programme began in the late 1970s at the Institute of Molecular Genetics (IMG-RAS) and the V.N. Orekhovich Institute of Biomedical Chemistry, where Myasoedov and Ashmarin “initiated studies to create a nootropic peptide preparation based on ACTH and its fragments” (Kolomin et al. 2013, Neuroscience and Medicine 4:223-252) 🔴 [Academic secondary source]. The finalised heptapeptide was first reported in indexed English-language literature by Potaman VN et al., Neurosci Lett 127(1):133-136 (1991), PMID 1652713, with the first behaviorally-focused paper following as Alekseeva EV et al., Neurosci Behav Physiol 22(6):475-479 (1992) [Peer-reviewed preclinical — Russian network] 🔴.

Russian Ministry of Health registration occurred in 1994 for cerebrovascular indications [Regulatory document — Russian GRLS]. Semax was added to Russia’s List of Vital & Essential Drugs (ЖНВЛП) on 7 December 2011 and retained in the 2026 federal EDL (Government Resolution № 3867-р of 18 December 2025) [Regulatory document].

Current marketing-authorisation holder: JSC «Peptogen» (Инновационный научно-производственный центр «Пептоген»), founded 2005 with participation of the IMG RAS, Moscow ⚠️ 🔴 [Regulatory document — manufacturer instruction PDFs filed with Roszdravnadzor].

Western entry into community discourse predates the modern Reddit nootropic era. The earliest substantive English-language community thread retrievable is a LongeCity “Semax review” thread posted in January 2005 (longecity.org/forum/topic/61943), placing Semax in active English-speaking biohacker discourse a full eight years before the BPC-157 / TB-500 / Selank wave hit r/Peptides. The Ceretropic vendor period (~2013–2016) deepened the community base; Reddit r/Nootropics adoption layered on top.

2025–2026 regulatory inflection. Three forces brought Semax back into Western view: (a) US Customs and Border Protection’s December 2025 – March 2026 Cincinnati operation explicitly named Semax in the public press release alongside MOTS-c, TB10, and cagrilintide; (b) HHS Secretary RFK Jr.’s 27 February 2026 Joe Rogan appearance (JRE #2461) named Semax among 14 peptides under FDA-reclassification discussion; (c) FDA Federal Register notice 16 April 2026 announcing PCAC review 24 July 2026 for proposed 503A Bulks-List inclusion.

---

3. Mechanism of Action

3.1 Demonstrated in humans

No mechanistic human study meeting modern receptor-occupancy or target-engagement standards has been published. The closest indexed English-language human pharmacodynamic data is Lebedeva IS, Panikratova YR et al., Bull Exp Biol Med 165(5):653-656 (2018), PMID 30225715, in which 14 healthy subjects on intranasal 1% Semax (vs 10 placebo) showed “a greater volume of the default mode network rostral (medial frontal cortex) subcomponent…in the Semax group in comparison with controls” — a structural-imaging readout, not direct target engagement 🔴 [Peer-reviewed human study]. Plasma BDNF elevation alongside clinical improvement has been reported in one 110-patient Russian post-stroke cohort (Gusev/Martynov 2018) — correlational, not mechanistic 🔴 ⚠️ [Peer-reviewed human study — Russian-language].

3.2 Proposed / preclinical

• BDNF / TrkB upregulation in rat hippocampus — 1.4-fold BDNF protein, 1.6-fold TrkB phosphorylation, ~3-fold BDNF mRNA after a single 50 µg/kg intranasal dose 🔴 [Peer-reviewed preclinical — Dolotov 2006 PMID 16996037; Dolotov 2006 J Neurochem PMID 16635254]. All replication is internal to the IMG-RAS network.
• NGF / neurotrophin co-regulation in hippocampus, frontal cortex and retina (Shadrina 2009 PMID 19662538) 🔴 [Peer-reviewed preclinical].
• Dopaminergic and serotonergic activation in rat striatum / cortex (Eremin 2005, Neurochem Res 30:1493) 🔴 [Peer-reviewed preclinical].
• Inhibition of enkephalin-degrading enzymes: Semax IC₅₀ 10 µM (Kost NV et al., Russ J Bioorg Chem 27:156-159 (2001), PMID 11443939) 🔴 [Peer-reviewed preclinical].
• Anti-inflammatory / immune-vascular transcriptome modulation in rat tMCAO (Medvedeva 2014 PMID 24661777; Filippenkov 2020 PMID 32580520; Sudarkina/Filippenkov 2021 IJMS 22:6179; Filippenkov 2024 PMC11673339) 🔴 ⚠️ [Peer-reviewed preclinical].
• Cu²⁺ coordination chemistry (Tabbì 2015 J Inorg Biochem 142:39) [Peer-reviewed preclinical — independent Italian group; one of the few non-Russian wet-lab studies on Semax].
• Aβ-aggregation modulation in artificial membranes (ACS Chem Neurosci 2021) [Peer-reviewed preclinical].
• Melanocortin MC4 / MC5 antagonism — claim derives entirely from Adan RA et al., Eur J Pharmacol 269(3):331-337 (1994), PMID 7895772 (Utrecht), which tested the chemically identical compound [Pro⁸,¹⁰,Gly⁹]ACTH(4-10) at cloned rat MC3R, human MC4R and ovine MC5R via cAMP functional assay using α-MSH displacement, and reported antagonism at MC4 and MC5 but not MC3; MC1R and MC2R were never assayed. No subsequent radioligand-binding, cAMP, β-arrestin or BRET study using Semax-branded material has been published. See Section 7.5.

Single-group dependency flag 🔴: With the exception of Tabbì 2015 (copper coordination chemistry, in vitro) and Adan 1994 (receptor pharmacology, in vitro, the [Pro⁸,¹⁰,Gly⁹]ACTH(4-10) test compound), the entire Semax preclinical efficacy literature traces to the IMG-RAS / Pirogov RNRMU / Tsyb MRRC network in Moscow.

---

4. Regulatory Status

Last regulatory review: 2026-05-17

4.1 Drug-regulatory status

Authority	Status (May 2026)
Russia (GRLS / Минздрав)	Approved. Semax 1% nasal drops — Р N000812/01-291211 (date suffix 29 Dec 2011); Semax 0.1% nasal drops — re-registered 26 March 2025 as ЛП-№(009449)-(РГ-RU), indefinite duration; holder JSC Peptogen ⚠️ 🔴 [Regulatory document — GRLS / Vidal / Peptogen instruction PDFs].
Belarus, Kazakhstan, Armenia, Kyrgyzstan	Registered (EAEU mutual-recognition pathway, carried over from pre-2022 national registrations) [Regulatory document — EAEU register].
Ukraine	Pre-2022 national registration; post-2022 practical availability disrupted [Regulatory document].
FDA (US)	Not approved. No NDA, no IND. Placed in 503A Category 2 September 2023; removed from Category 2 effective 22–23 April 2026 after nominator withdrawal; scheduled for PCAC review 24 July 2026 (Docket FDA-2026-N-2979; comment docket FDA-2025-N-6895) for proposed 503A Bulks-List inclusion for cerebral ischemia, migraine, and trigeminal neuralgia [Regulatory document — FDA Federal Register 16 April 2026]. Material regulatory change since prior review.
EMA	No application on file [Regulatory document — EMA register].
MHRA (UK)	Unauthorised medicine [Regulatory document — MHRA register].
Health Canada	No DIN issued; not on Prescription Drug List [Regulatory document — Health Canada DPD].
TGA (Australia)	No ARTG entry. Not separately scheduled in the Therapeutic Goods (Poisons Standard — October 2025) Instrument 2025 (SUSMP); covered by the general TGA consumer warning on unapproved peptide imports [Regulatory document — TGA SUSMP October 2025].
PMDA (Japan), NMPA (China), MFDS (Korea)	No approvals identified.

4.2 Anti-doping status

Body	Status
WADA 2026 Prohibited List	NOT listed in S0–S9, M1–M3 or P1–P2 [Anti-doping document — WADA 2026 Prohibited List, approved 11 Sep 2025, in force 1 Jan 2026].
WADA 2026 Monitoring Program	NOT listed [Anti-doping document — WADA 2026 Monitoring Program].
In-competition / out-of-competition	Not prohibited at either time. Athletes remain bound by strict-liability; intranasal peptide products carry contamination risk with prohibited growth-factor analogs.
TUE eligibility	Not applicable — Semax is not prohibited, so no TUE is required.
NCAA Banned Drugs List 2025–26	Not specifically listed [Anti-doping document — NCAA 2025-26].
DoD-OPSS / Operation Supplement Safety	Unapproved drug; service-members are prohibited from use under DoD policy on unapproved peptides regardless of WADA status [Anti-doping document — OPSS 2026 peptide guidance].
Global DRO (checked 2026-05-17)	“Semax” not returned as a recognised medication in US/UK/CA/AU/JP/CH/NZ databases; recommended treatment as high-risk unrecognised peptide [Anti-doping document — globaldro.com].
BSCG	Identified among peptides on the BSCG 2026 peptide-regulation summary; not in any BSCG Certified Drug Free product [Anti-doping document — BSCG].
TGA scheduling (Australia)	Not scheduled in SUSMP October 2025; TGA consumer warning applies to unapproved peptide imports [Regulatory document — TGA].

4.3 US compounding pathway after PCAC consolidation

• Pre-April 2026: Semax was on the 503A Category 2 list (since September 2023); compounding effectively prohibited.
• 22–23 April 2026: Removed from Category 2 because the nominator withdrew the nomination. Removal does not authorise compounding.
• 24 July 2026 (upcoming): PCAC will vote on inclusion on the Section 503A Bulks List for cerebral ischemia, migraine, trigeminal neuralgia. PCAC vote is advisory; final inclusion requires FDA notice-and-comment rulemaking that historically takes >12 months. Comment docket FDA-2025-N-6895 closes 22 July 2026 [Regulatory document].
• 503B outsourcing facilities: FDA has been silent on parallel 503B Category 1 inclusion; outsourcing-facility compounding therefore remains effectively unavailable.

---

5. Formulations and Routes

Product	Strength	Approx. dose/drop	Use category	Status
Семакс 0.1% nasal drops	1 mg/mL	~50 µg	Nootropic / asthenic / encephalopathy	Russia-approved
Семакс 1% nasal drops	10 mg/mL	~500 µg	Acute ischemic stroke; optic-nerve disease	Russia-approved

Subcutaneous / IM formulations referenced in nootropic and research literature are investigational only, not GRLS-registered. Plasma t½ in humans is reported in the minutes range; intranasal CNS access is presumed via olfactory and trigeminal pathways, with downstream BDNF/NGF effects persisting 12–24 h in rodent models 🔴 [Peer-reviewed preclinical — Dolotov 2006; Shadrina 2009].

---

6. Preclinical Evidence

• Rat tMCAO (focal ischemia): Reduced infarct volume, improved neurological score; transcriptome modulation favouring immune/vascular pathways (Medvedeva 2014; Filippenkov 2020, 2021, 2024) 🔴 ⚠️ [Peer-reviewed preclinical].
• Passive-avoidance / Morris water-maze learning enhancement in rats; antidepressant-like and anxiolytic-like effects in FST and EPM 🔴 [Peer-reviewed preclinical — Inozemtseva 2024 Eur J Pharmacol 984:177068].
• Cu²⁺ coordination chemistry (Tabbì 2015 — independent Italian group) [Peer-reviewed preclinical].
• Aβ-aggregation modulation in artificial membranes (ACS Chem Neurosci 2021) [Peer-reviewed preclinical].
• Limitations: Predominantly single-network (IMG-RAS / Pirogov RNRMU / Tsyb MRRC) replication; no large NIH/NINDS STAIR-compliant Western preclinical replication of stroke endpoints.

---

7. Clinical Evidence

7.1 Cochrane systematic reviews

None identified. A 1997 Skvortsova trial (Zh Nevrol Psikhiatr Korsakova 97(6):26–34) is indexed in CENTRAL but no Cochrane SR on Semax has been published as of 2026-05-17 [Cochrane SR — none identified].

7.2 Randomised controlled trials (English-indexed)

• No double-blind placebo-controlled Phase 2/3 RCT of Semax has been published in indexed English-language literature [confirmed 2026-05-17].
• Russian-language sources cite multiple randomised or quasi-randomised hospital trials underpinning the 1994 registration (Skvortsova, Gusev, Myasoedov) 🔴 ⚠️ [Peer-reviewed human study — Russian-language]. The “120-patient placebo-controlled” stroke trial widely cited in secondary literature was not located under that description in PubMed.

7.3 Observational / open-label

• Polunin GS et al. 1999 — open-label Semax 0.1% vs basic therapy in optic-nerve disease (vascular, toxic-allergic, inflammatory, partial atrophy); improved visual acuity, visual fields, electrical conductivity 🔴 [Peer-reviewed human study — Vestn Oftalmol PMID 10741256].
• Gusev EI, Martynov MY, Kostenko EV et al. 2018 — 110 patients post-ischemic stroke; Semax 6,000 µg/day × 10 d × 2 courses raised plasma BDNF and improved MRC motor and Barthel index scores 🔴 ⚠️ [Peer-reviewed human study — Russian-language]. Semax+ vs Semax− subgroup design, not conventional placebo control.
• Kurysheva 2001; Sheremet 2004 — glaucoma / optic neuropathy adjunct use 🔴 [Peer-reviewed human study — Russian-language].
• Lebedeva IS et al. 2018 (PMID 30225715) — 14 healthy subjects on intranasal 1% Semax vs 10 placebo; DMN volumetric MRI changes 🔴 [Peer-reviewed human study — Bull Exp Biol Med]. The only indexed English-language healthy-volunteer Semax study located.
• Healthy-volunteer Russian-language operator/student studies: The frequently cited 250–1,000 µg/kg attention/short-term memory effects derive from sources reviewed in Kolomin TA et al. 2013, which the ADDF Cognitive Vitality monograph notes “cannot access, in Russian” 🔴 [Academic secondary source].
• No Western academic principal investigator has registered or published primary Semax clinical data 2023–2026 [Clinical trial registry — none identified on ClinicalTrials.gov, EU CTR, ICTRP].

7.4 Trial registry status (CT.gov + ICTRP, 2026-05-17)

No interventional trial of Semax sponsored by a Western or industry sponsor is registered. No FDA IND. No EMA CTIS entry.

7.5 Disputed Claims

1. BDNF / TrkB upregulation — single-network dependency. The canonical Dolotov 2006 finding (PMID 16996037, Brain Research) and the companion J Neurochem radio-binding paper (PMID 16635254) both originate at IMG-RAS. Follow-up rat-brain and retina papers (Shadrina 2009, Filippenkov 2020–2024) reinforce the finding but all share author overlap with the originating group 🔴. No independent Western or Asian laboratory has published a confirmatory hippocampal BDNF/TrkB upregulation experiment after intranasal Semax as of 2026-05-17. Status: unresolved — single-network finding with internal replication only.

This is the same archetypal pattern documented for BPC-157 (Sikiric/Seiwerth dependency) and Thymalin/Epitalon (Khavinson framework). The community-marketing magnitude — repeatedly cited as “800% BDNF upregulation” — does not come from Dolotov 2006 (which reported 1.4-fold = 40% increase). It traces specifically to Shadrina et al. 2001, Neurosci Lett 308(2):115–118, PMID 11457573, an in-vitro study of glial cells from neonatal rat basal forebrain — not adult human, not adult rat hippocampus, not in vivo. The community has propagated the in-vitro neonatal-glial figure as if it were a human-extrapolatable adult-brain effect.

2. Stroke-registration evidence base — Western methodological critique. The Alzheimer’s Drug Discovery Foundation Cognitive Vitality monograph states verbatim: “Neuroprotective Benefit: Semax may be beneficial in stroke patients (and is used for stroke in Russia), but published literature of well-conducted studies is lacking.” No formal Cochrane SR has examined the registration-supporting trials, and no STAIR-compliant Western preclinical or Phase 3 replication exists. There is no published Western neurology paper alleging fraud, but the consensus that the evidence is insufficient by Western Phase 3 standards is explicit [Academic secondary source — ADDF Cognitive Vitality]. Status: ongoing methodological dispute.

3. MC4 / MC5 partial-agonist / antagonist claim. The entire claim rests on Adan et al. 1994 (PMID 7895772, Utrecht), which tested [Pro⁸,¹⁰,Gly⁹]ACTH(4-10) (= Semax in sequence) at MC3R / MC4R / MC5R and reported antagonism at MC4 and MC5, not agonism. Bertolini 2012 (PMID 22293371) and downstream secondary sources (Wikipedia; vendor monographs) propagate the citation but no subsequent direct binding / cAMP / β-arrestin assay using Semax-labelled material has been published. The “partial agonist” framing in some secondary sources is not supported by Adan 1994, which reported pure antagonism at MC4/MC5. Status: under-supported by modern receptor pharmacology standards.

This third dispute matters at the community level because the single LongeCity testimonial linking Semax to libido / sexual-attraction effects (AlexCanada, December 2015) explicitly invoked “MC4 receptors” — a mechanism the actual receptor data does not support and which Adan 1994 demonstrably contradicts (antagonism, not agonism).

---

7B. Community Evidence Layer

(See Pass 2 for full source detail. This section condenses the substantive layer; retrieval limitations are preserved in Section 13.)

Trajectory. Stable-to-rising. The Western community footprint pre-dates Reddit — the LongeCity “Semax review” thread is dated January 2005 — and has been continuous since. Three subcommunities converge: cognitive-enhancement / ADHD-adjacent nootropic users (LongeCity, r/Nootropics, David Tomen, Jonathan Roseland, Mansal Denton); longevity / Russian-peptide enthusiasts (CosmicNootropic, Ben Greenfield, Nathalie Niddam); and a smaller bodybuilding / SubQ subgroup (MuscleChemistry, LongeCity SubQ stack threads).

Modal community protocol. Russian 0.1% drops at “2 drops per nostril × 2× daily” ≈ 400–600 µg/day intranasal; 10–14 day cycles with breaks. This dose maps directly to the Russian package insert and has been stable since the LongeCity 2005 review. Stroke-recovery framing pushes 2,000–3,000+ µg/day; cognitive use stays at 500–1,500 µg/day. SubQ doses are 0.5–2 mg/day per LongeCity 2014–2017 reports — a route the Russian regulatory file does not cover.

Top-claimed effects (with frequency): improved focus / mental clarity (widespread); verbal fluency, faster speech/writing (common); working-memory and recall improvements (common); ADHD-like symptom relief and stimulant potentiation (common but contested); mood lift / anhedonia relief (common); mild anxiolysis / stress resilience (common); “subtle” rather than “noticeable” effect (widespread split).

Top-reported side effects: nasal irritation / mucosal burning (common, mild); headache at higher dose (common); overstimulation / anxiety at higher dose (common); methylphenidate-like “crash” / rebound (occasional); no-effect / non-responder (notable subgroup); tolerance / diminishing returns (occasional); hair thinning (single-source / CosmicNootropic FAQ explicitly addresses Reddit reports); sleep disturbance if dosed late (occasional); one seizure outlier (LongeCity 2022 — not corroborated).

Community dissent that has never narrowed. Five splits running for 15+ years:

1. “Works great” vs “complete placebo” — both camps coexist in the same LongeCity master thread. “Two or three drops equals 5 ml IM cerebrolysin” (2005) and “Wasted £80 on the higher strength nasal bottle. It had no affect on me” (2013) sit side by side.
2. Semax vs N-Acetyl Semax vs N-Acetyl Semax Amidate — see two-molecule block above. The Russian-Rx camp considers only Peptogen-manufactured material legitimate; Ceretropic-era users treat all three as a family.
3. Intranasal vs subcutaneous — Russian-Rx camp insists intranasal only; LongeCity / MuscleChemistry SubQ users defend the injection route as more convenient and effective.
4. Russian-Rx credibility — does the GRLS registration mean anything for a Western user? CosmicNootropic, Swolverine, and Ben Greenfield treat the decades of registration as a strong signal. RethinkPeptides and SelfDecode point out the clinical evidence package would not pass FDA / EMA standards.
5. The BDNF magnitude claim — see Section 7.5 dispute #1. Some community-edge writers (Limitless Mindset, Nootropics Expert) push back on the “800% BDNF” figure; vendor pages continue to lead with it.

Stack patterns. The canonical stack is Semax + Selank (“gas pedal vs traction control” per LIVV Natural). Also common: Semax + racetams (piracetam, aniracetam, phenylpiracetam); Semax + modafinil; Semax + Cerebrolysin (the “Russian stack”); Semax + stimulants (Vyvanse, Ritalin, Adderall) for ADHD-adjacent users; Semax + caffeine / nicotine as base pairing.

Vendor landscape. The historical leader is CosmicNootropic (Russia-based, sells authentic Peptogen-manufactured product). Ceretropic (now defunct) was the canonical US-side mid-2010s vendor. Pure Nootropics has delisted Semax from its 2026 catalog. Nootropics Depot has never carried it — a signal of the cautious end of the supply chain. Active Western research-chemical vendors include Limitless Life Nootropics, Nootropic Source, Pure Bio Labs, Peptide Sciences, Mind Nutrition (UK), Cerebral Health (UK). Medically-supervised compounding-pharmacy channels (RWA Center Beverly Hills; LIVV Natural) opened in the 2025–2026 PCAC-window. The December 2025 – March 2026 CBP Cincinnati seizure named Semax explicitly and changed the import-risk calculus.

The Russian-Rx halo effect. The single most distinctive feature of Semax community discourse. CosmicNootropic and the Russian-Rx camp lean hard on “this isn’t a research peptide, it’s an actual approved drug.” Western-skeptic writers note the GRLS evidence base would not satisfy modern FDA / EMA standards. Wikipedia sits in the middle. This halo drives premium pricing for authenticated Peptogen product and shapes the community’s QC vigilance — the “purity COA + endotoxin COA + sterility COA” three-document standard that Limitless Life now publishes per lot.

Mainstream-podcast canon is conspicuously thin. Andrew Huberman has not meaningfully discussed Semax on Huberman Lab. Peter Attia, Tim Ferriss, Joe Rogan (in his own voice), Layne Norton, and Nathalie Niddam likewise have no dedicated Semax coverage. The only mainstream-podcast naming located is RFK Jr.’s 27 Feb 2026 reference on JRE #2461 — and that was a regulatory list, not a use endorsement. This podcast-canon absence is itself a finding and is the single largest reason Semax sits at Community Tier B/71 rather than A despite its 20+ year footprint.

---

8. Safety Profile

• Common AEs: Mild nasal irritation, occasional headache, transient excitation/insomnia if dosed late in the day, dysgeusia [Regulatory document — Russian SmPC; Peer-reviewed human study — Polunin 1999].
• HPA-axis claim: Semax is described as non-cortisotropic because ACTH(4-10) lacks the C-terminal segment required for MC2R adrenal activation. Direct measurement of human plasma cortisol after intranasal Semax has not been published in indexed Western literature 🔴 — claim is mechanistically plausible but human pharmacodynamic confirmation is sparse.
• Diabetics: ADDF and Russian SmPC note possible transient blood-glucose elevation; caution advised.
• Pediatric use: Approved in Russia for perinatal encephalopathy and selected developmental disorders; no Western pediatric controlled data 🔴 [Regulatory document — Russian SmPC].
• Pregnancy / lactation: Russian SmPC contraindicates; no controlled human data.
• Trial exclusions: Russian stroke trials typically excluded hemorrhagic stroke, severe psychiatric disease, uncontrolled hypertension.
• Retractions identified: None as of 2026-05-17 [Bibliographic check — PubMed retraction watch].
• Western pharmacovigilance: No FAERS, EudraVigilance, or Yellow Card dataset (substance not marketed in those jurisdictions). Compounded-peptide adverse-event signals — immunogenicity, endotoxin contamination — flagged generically in FDA PCAC briefing December 2024, not Semax-specific [Regulatory document — FDA PCAC 4 Dec 2024 transcript].

Community-reported AEs requiring science-layer attention.

1. Hair thinning / hair loss — CosmicNootropic FAQ explicitly addresses Reddit reports: “no official data supporting this correlation.” Mechanistically speculative via BDNF / growth-factor signaling. Not characterised.
2. “Stopped working” / tolerance — Ben Greenfield podcast and LongeCity threads describe diminishing returns over multi-week continuous use; pharmacodynamic mechanism (receptor desensitization?) not characterised.
3. Methylphenidate-like crash / rebound — single LongeCity datapoint at higher SubQ dose; not characterised.
4. One LongeCity user 2022 reported seizure — single anomalous report; not corroborated.

---

9. Drug Interactions

No formal human DDI studies. Theoretical interactions reasoned from mechanism:

• Dopaminergic stimulants (amphetamine, methylphenidate): preclinical potentiation of locomotor response in rodents; clinical relevance unknown 🔴 [Peer-reviewed preclinical]. Strongest LongeCity datapoint: 30 mg Vyvanse user reported stimulant-effects-without-side-effects with daily SubQ Semax; counter-datapoint: GAD user with 500 µg Semax + Ritalin reported increased anxiety.
• SSRIs: Overlapping serotonergic modulation; no reported clinical syndrome.
• Anticonvulsants: No reported interaction.
• Insulin / oral hypoglycaemics: Monitor glucose given anecdotal hyperglycaemia signal.
• CYP450: Peptide; not expected to inhibit/induce major CYPs; no formal study.

---

10. Research Gaps

1. Independent Western or Asian replication of the BDNF / TrkB hippocampal upregulation finding — absent for ≥20 years.
2. Direct human pharmacodynamic measurement of plasma BDNF, cortisol, and dopamine metabolites after intranasal dosing with modern bioanalytical methods.
3. STAIR-compliant preclinical stroke replication in non-Russian laboratories.
4. Double-blind placebo-controlled Phase 2/3 RCT in acute ischemic stroke meeting modern Western standards (ECASS / ESCAPE-like design).
5. Modern receptor pharmacology (radioligand binding, cAMP, β-arrestin, BRET) at MC1–MC5 with Semax-branded material, including MC1R and MC2R which were never assayed by Adan 1994.
6. Cognitive-enhancement RCT in healthy adults with pre-registered cognitive battery and adequate sample size beyond Lebedeva 2018 (n = 24 total).
7. PK/PD characterisation of intranasal vs subcutaneous administration in non-Russian healthy volunteers.
8. Long-term safety dataset beyond 30-day intermittent courses.
9. ADHD efficacy dataset in English — Russian pediatric clinical experience exists but is not published in indexed English-language RCTs.
10. Direct PK/PD characterisation of N-Acetyl Semax and N-Acetyl Semax Amidate vs heptapeptide Semax in humans — currently a vendor-driven dose-equivalency claim with no published bridging data.
11. Mechanistic characterisation of the “hair thinning” community signal if real.
12. Tachyphylaxis / receptor-desensitization evaluation of the community-reported “stopped working” pattern.

---

11. Bottom-Line Encyclopedia Note (≤150 words)

Semax (ACTH(4-7)PGP) has been a registered Russian prescription medicine since 1994 for acute ischemic stroke, encephalopathy, optic-nerve disease and cognitive disorders, and on Russia’s List of Vital & Essential Drugs since December 2011. Preclinical evidence for BDNF/TrkB upregulation, anti-inflammatory transcriptome modulation and post-ischemic neuroprotection is internally consistent but originates almost entirely from a single Russian network. No Cochrane systematic review, no Western-standard double-blind Phase 3 RCT, and no FDA or EMA approval exist. The substance is not on the WADA 2026 Prohibited List or Monitoring Program. In the US, it was removed from FDA 503A Category 2 in April 2026 and is under PCAC review on 24 July 2026 for possible Bulks-List inclusion for cerebral ischemia, migraine and trigeminal neuralgia. Evidence quality is uneven across indications; independent Western mechanistic and clinical replication remains the principal outstanding gap.

---

11B. Gap Analysis — Where Science and Community Diverge

Semax sits in the High community + Low science cell of the gap matrix. The science / community delta (C/15 cognitive vs B/71, Δ = 56 points) is substantial but smaller than BPC-157 (Δ = 78) or TB-500 (Δ = 77) — because Semax has a real regulatory anchor that BPC-157 and TB-500 lack, and that anchor counts for something even if it doesn’t translate to Western standards.

Subclass assignment (v4 4-cell matrix):

• Primary: Subclass 1 — Community ahead of [Western] science. Canonical for the BPC-157 archetype. The molecule has been extensively studied — in Russia, by a single network, with internally consistent positive results — but the entire evidence base would not pass a Western Phase 3 review. The Western community has codified a protocol on top of an evidence package the Western regulatory regime does not validate. Semax is effectively a BPC-157-type case with a Russian regulatory veneer that doesn’t translate.
• Secondary: Subclass 3 — Indication divergence. Semax has Russian regulatory data for stroke, encephalopathy, optic-nerve disease, and pediatric perinatal encephalopathy. The Western community modal use is healthy-adult cognitive enhancement and ADHD-adjacent application — indications that partially overlap with the Russian “asthenic syndrome” framing but are not the same as the registered acute-ischemic-stroke or post-stroke-rehabilitation indications. Healthy-adult nootropic use, as practiced by the Western community, sits inside the Russian “asthenic” umbrella conceptually but has no dedicated controlled Western RCT.

Topic	Science Layer	Community Layer	Gap
Cognitive enhancement in healthy adults (the modal Western community use)	One indexed English-language study: Lebedeva 2018 PMID 30225715, n=24, DMN structural-imaging readout 🔴. Russian-language operator/student studies cited at second-hand via Kolomin 2013; ADDF Cognitive Vitality notes “cannot access, in Russian."	"Best smart drug I’ve tried” / “verbal fluency improved” / “memorize faster, read faster” — David Tomen, Limitless Mindset, LongeCity 2005–2022, Ben Greenfield.	🔴 MAJOR GAP — community ahead of Western science. The community claim has not been tested in adequately powered controlled Western trials. Russian-language single-network data exists but is inaccessible to Western evaluators by language barrier alone.
Stroke (acute ischemic, the headline Russian regulatory indication)	Russian-language registration trials (Skvortsova / Gusev / Myasoedov, 1990s); Gusev 2018 Zh Nevrol Psikhiatr Korsakova 110-patient post-stroke cohort with semax+ vs semax− subgroup design 🔴 ⚠️. No Cochrane SR. No STAIR-compliant Western preclinical replication. No Western Phase 2/3 RCT.	Not the modal Western community use, but the FDA PCAC 24 July 2026 docket explicitly targets cerebral ischemia.	Subclass 1 again — community would be ahead of Western science if community adopted this indication, but community has largely not. The community uses the molecule the regulatory file supports least well for the modal Western audience.
BDNF mechanism (community marketing centerpiece)	Single-network: Dolotov 2006 PMID 16996037 hippocampus 1.4-fold protein increase 🔴; Shadrina 2001 PMID 11457573 in-vitro neonatal glial cells; Filippenkov 2020–2024 transcriptome 🔴. No independent Western or Asian replication in 20+ years.	Vendor pages, biohacker blogs, and CosmicNootropic propagate “Semax raises BDNF 800%” as the canonical marketing claim.	Magnitude misattribution. The “800%” figure is the in-vitro neonatal-glial Shadrina 2001 number; the in-vivo adult-rat hippocampus number (Dolotov 2006) is 1.4-fold. The mechanism is being sold as the effect, and the wrong magnitude is being sold as the mechanism.
MC4/MC5 mechanism	Adan 1994 PMID 7895772 reported antagonism at MC4/MC5 using [Pro⁸,¹⁰,Gly⁹]ACTH(4-10) (= Semax in sequence). No replication of receptor pharmacology with Semax-labelled material in 30+ years. MC1R and MC2R never assayed.	Single LongeCity testimonial (AlexCanada Dec 2015) attributes libido / sexual-attraction effects to “MC4 receptors.” Some secondary sources propagate “partial agonist” framing that the actual data does not support.	Mechanism citation chain broken. Adan reported antagonism; secondary sources say partial agonism; community then layers behavioral claims (libido) on top of the secondary mischaracterization.
ADHD utility	No English-language RCT. Russian pediatric clinical experience exists for “perinatal encephalopathy” not ADHD-specifically. SelfDecode/SelfHacked: “many additional studies will be needed to determine if there is a benefit.”	David Tomen / Nootropics Expert (self-disclosed Adult-ADD) treats Semax as an ADHD-utility tool. LongeCity Vyvanse-stacking and Ritalin-stacking threads converge on stimulant-potentiation framing.	Community indication has no Western RCT and only oblique Russian evidence. The strongest single LongeCity datapoint (the Vyvanse + SubQ Semax user) is uncorroborated and uncontrolled.
Hair thinning (community-reported AE)	Not characterised in any clinical literature.	CosmicNootropic FAQ explicitly addresses Reddit reports.	Community-only signal that science has not addressed.
Tolerance / “stopped working”	Not characterised. No pharmacodynamic mechanism in literature.	Ben Greenfield + Jean-François Tremblay podcast and LongeCity threads converge on cycling rationale.	Community-only signal that science has not addressed.
Russian-Rx halo effect (community claim)	Russian GRLS registration since 1994 is documented. ADDF notes “used for stroke in Russia, but published literature of well-conducted studies is lacking."	"This isn’t a research peptide, it’s an actual approved drug” — CosmicNootropic, Swolverine, Ben Greenfield.	Aligned at the regulatory fact, divergent at the interpretation. The Rx anchor exists; whether that anchor justifies the Western community’s confidence depends on whether one accepts the Russian evidence base as Western-grade. The community accepts; ADDF / RethinkPeptides / SelfDecode do not.

Net characterisation. Semax is a BPC-157-archetype case (single-network preclinical, no Western RCT) with a Russian regulatory veneer that doesn’t translate to Western evaluation standards. The Russian Rx halo gives Semax something BPC-157 doesn’t have — three decades of pharmacovigilance in a regulated market, a manufacturing pedigree (JSC Peptogen), and a List of Vital & Essential Drugs designation — and that pedigree is the single largest factor differentiating Semax’s community discourse from BPC-157’s grey-market frontier feel. But the underlying methodological hole is the same: a community has built a 20-year protocol on top of a preclinical evidence base owned by one research network whose work has never been independently replicated outside its own author block. The three highest-consequence gaps:

1. The modal Western community indication — healthy-adult cognitive enhancement — has not been tested in adequately powered Western RCTs. The only indexed English-language healthy-volunteer Semax study (Lebedeva 2018) is n=24 with a structural-imaging readout, not a cognitive performance endpoint.
2. The BDNF magnitude claim that drives community marketing (800%) is the wrong number from the wrong tissue from the wrong life stage — Shadrina 2001 in-vitro neonatal glia, not Dolotov 2006 in-vivo adult hippocampus. Community marketing has sold the in-vitro neonatal number as the in-vivo adult effect.
3. The Russian Rx halo is doing significant interpretive work that the actual evidence base may not support. The community’s “30 years of safety experience in millions of Russian patients” is a real fact about Russian healthcare; whether it generalises to a Western user dosing 500–1,500 µg/day intranasally for nootropic purposes is a separate question the data does not directly answer.

A community pattern worth noting: Semax’s continuous Western community footprint since 2005 has produced a richer informal pharmacovigilance dataset (effect descriptors, non-responder reports, hair-thinning signal, tolerance pattern, “stress-without-anxiety” framing) than any of the Western controlled trials. The community has been gathering signal that the literature is silent on — same as BPC-157, but over a longer timeline.

---

12. Three Paths

You choose your risk tolerance. This monograph provides the data, not the recommendation.

Conservative path — wait. Defined as: not engaging until at least one of (a) a Western Phase 2/3 double-blind placebo-controlled RCT in cognitive enhancement or stroke, (b) FDA / EMA / MHRA approval in any indication, (c) independent Western or Asian replication of the Dolotov 2006 BDNF/TrkB hippocampal finding, (d) Cochrane systematic review of the existing Russian evidence base, or (e) the 24 July 2026 PCAC outcome producing a clear 503A Bulks-List pathway. All five gates are pending as of 17 May 2026. Semax does not meet the conservative bar. Conservative-path users wait.

Moderate path — Tier C with monitoring. Defined as: treating Semax as a Tier-C compound with a real Russian regulatory anchor, preclinical mechanistic plausibility, single-network dependency in the evidence base, no Western RCT confirmation, and an unresolved series of community-reported AEs (hair thinning, tolerance, methylphenidate-like rebound at higher dose) that the literature is silent on. This path means: source from the Russian Peptogen pedigree where possible (i.e., authenticated CosmicNootropic supply) rather than research-chemical grey market, with awareness of the December 2025 – March 2026 CBP Cincinnati seizure precedent; start at the Russian package-insert intranasal dose (50 µg/drop × 2 drops × 2× daily ≈ 200–400 µg/day) rather than the LongeCity SubQ heavy-dose patterns; cycle 10–14 days on / 1–2 weeks off rather than continuous use, anchored in both the Russian instruction and Greenfield/Tremblay diminishing-returns framing; baseline cognitive self-assessment before starting; explicit non-use during pregnancy/lactation (Russian SmPC contraindication); explicit non-use for any WADA-tested athlete during periods of contamination-risk concern (Semax itself is not prohibited but compounded intranasal peptide products carry contamination risk with prohibited growth-factor analogs); awareness that the “amidate” and “N-acetyl” variants are not the same molecule as Russian Peptogen Semax.

High-tolerance path — grey-market with mitigation. Defined as acknowledging that none of the five conservative gates are met, that the entire preclinical efficacy literature is owned by one Russian network, and that the Western community evidence is anecdotal even if 20+ years deep. The community mitigation stack documented in Pass 2: third-party COA verification — purity, endotoxin, sterility — preferring vendors that publish per-lot rather than per-brand certificates (Limitless Life’s three-document standard); preference for the Russian Peptogen 0.1% product over Western research-chemical-vendor product where supply chain allows, on the basis of 30 years of regulated manufacturing rather than research-chemical sourcing; titration starting at 100–200 µg/day intranasally rather than headline LongeCity SubQ doses; cap at the low end of the community range (≤600 µg/day) for cognitive-enhancement use; explicit avoidance of the SubQ route in absence of clinical supervision; awareness that the “Russian-Rx halo” the community invokes is doing significant interpretive work, that Russian GRLS evidence standards differ materially from FDA / EMA, and that the 30-year safety record applies to a regulated intranasal indication, not to indefinite-duration daily off-label nootropic use; awareness of the post-2025 import-risk shift after the CBP Cincinnati seizure naming Semax explicitly; explicit non-use for any WADA-tested athlete or DoD service member regardless of WADA status (DoD prohibits unapproved peptides categorically).

---

13. Key References

Scientific (Pass 1 layer)

Regulatory documents:

• FDA Federal Register Notice 16 April 2026, Docket FDA-2026-N-2979 / FDA-2025-N-6895; PCAC meeting 23–24 July 2026.
• FDA Interim 503A Bulks-List Guidance, January 2025.
• FDA PCAC 4 December 2024 transcript.
• TGA Therapeutic Goods (Poisons Standard — October 2025) Instrument 2025.
• Russian GRLS: Semax 1% Р N000812/01-291211; Semax 0.1% ЛП-№(009449)-(РГ-RU) re-registered 26 March 2025; holder JSC Peptogen.
• Russian List of Vital & Essential Drugs (ЖНВЛП), Semax included since 7 December 2011; carried in 2026 federal EDL Resolution № 3867-р of 18 December 2025.

Anti-doping documents:

• WADA 2026 Prohibited List + Monitoring Program (in force 1 January 2026). Semax: not listed.
• NCAA Banned Drugs List 2025–26.
• DoD-OPSS 2026 peptide guidance.
• Global DRO cross-check, 17 May 2026.
• BSCG 2026 peptide-regulation summary.

Peer-reviewed mechanistic / receptor pharmacology:

• Potaman VN et al. Neurosci Lett 127(1):133-136 (1991). PMID 1652713. 🔴
• Alekseeva EV et al. Neurosci Behav Physiol 22(6):475-479 (1992). DOI 10.1007/BF01186122. 🔴
• Adan RA et al. Eur J Pharmacol 269(3):331-337 (1994). PMID 7895772. [The receptor pharmacology paper — antagonism at MC4/MC5.]
• Kost NV et al. Russ J Bioorg Chem 27:156-159 (2001). PMID 11443939. 🔴
• Dolotov OV et al. J Neurochem 97(Suppl 1) (2006). PMID 16635254. 🔴
• Dolotov OV et al. Brain Research 1117(1):54-60 (2006). PMID 16996037. 🔴
• Shadrina MI et al. Neurosci Lett 308(2):115-118 (2001). PMID 11457573. [The original source of the community’s “800% BDNF” figure — in vitro neonatal glial cells.]
• Shadrina MI et al. (2009). PMID 19662538. 🔴
• Tabbì G et al. J Inorg Biochem 142:39 (2015). [Independent Italian group.]
• Bertolini A. Eur J Pharmacol 679(1-3):1-8 (2012). PMID 22293371. [Secondary review propagating partial-agonist framing.]
• Inozemtseva LS et al. Eur J Pharmacol 984:177068 (1 December 2024). 🔴

Peer-reviewed clinical (Russian-network):

• Polunin GS et al. Vestn Oftalmol 116(1):15-18 (2000). PMID 10741256. 🔴
• Gusev EI, Martynov MY et al. Zh Nevrol Psikhiatr Korsakova 118(3 Pt 2):61 (2018). 🔴 ⚠️
• Lebedeva IS et al. Bull Exp Biol Med 165(5):653-656 (2018). PMID 30225715. 🔴

Preclinical (Russian-network transcriptome / stroke):

• Medvedeva EV et al. BMC Genomics 15:228 (2014). PMID 24661777. 🔴
• Filippenkov IB et al. Genes (Basel) 11(6):681 (2020). PMID 32580520. 🔴
• Sudarkina/Filippenkov IB et al. IJMS 22(12):6179 (2021). 🔴
• Filippenkov IB et al. Genes 15(12) (2024). PMC11673339. 🔴

Reviews / secondary sources:

• Kolomin TA et al. Neuroscience and Medicine 4(4):223-252 (2013). 🔴
• ADDF Cognitive Vitality Semax monograph.
• Cochrane Library — no SR identified for Semax (search 2026-05-17). None.
• ClinicalTrials.gov / EU CTR / ICTRP — no Semax interventional registration (2026-05-17). None.

Community (Pass 2 layer)

Foundational forum threads (LongeCity, 2005–2022):

• LongeCity “Semax review” (forum/topic/61943), January 2005 — foundational English-language community thread.
• LongeCity “Semax experiences?” (forum/topic/73451), 2013–2022 master thread, multiple pages.
• LongeCity “Semax Review – 2 weeks” (forum/topic/73230), 2014 SubQ Vyvanse-stacker report.
• LongeCity “Semax regimen” (forum/topic/69956), 2013 half-life debate.
• LongeCity “Ceretropic semax?” (forum/topic/75262).
• LongeCity “Anyone tried Semax?” (forum/topic/62390), 2013 non-responder.
• LongeCity “Semax: New Unique Info and detailed FAQ” (forum/topic/112351).

Vendor / community-aggregator content:

• CosmicNootropic, Semax product page; “Semax Review and Answering FAQs”; “PEPTOGEN IN DETAILS”; “Biohackers Favorites: David Tomen” pages (accessed 2026-05-17).
• Limitless Life Nootropics, Semax 30 mg nasal spray product page (limitlesslifenootropics.com).
• Nootropic Source, Pure Bio Labs, Peptide Sciences product pages (accessed 2026-05-17).
• Swolverine “Semax Dosing Guide” (accessed 2026-05-17).
• Peptides.org N-Acetyl Semax Amidate Dosage Calculator and reviews (accessed 2026-05-17).
• David Tomen / Nootropics Expert (nootropicsexpert.com).
• Jonathan Roseland / Limitless Mindset Semax review and podcast.
• Wholistic Research, “Semax Review” (accessed 2026-05-17).
• World of Peptides, “Semax Review Nootropic Benefits” (accessed 2026-05-17).
• PeptideDeck, Klearmind Clinics, Parahealth, RethinkPeptides, SelfDecode/SelfHacked, HealingMaps, MuscleChemistry.com forum, Peptide Affect, Wikipedia “Semax” (accessed 2026-05-17).
• ThePeptideCatalog, “FDA peptide reclassification 2026” — RFK Jr. on JRE #2461 (27 Feb 2026).
• Ben Greenfield Life, “Peptides Resource Page,” “The Best Peptide Stacks,” “The Peptides Podcast” with Jean-François Tremblay (accessed 2026-05-17).
• LIVV Natural, “Selank vs Semax” — “gas pedal vs traction control” framing.
• RWA Center, “Semax Peptide: Nasal Spray vs Injectable” — US-based clinical supervision.

Government / enforcement:

• US Customs and Border Protection, “Cincinnati CBP foils scheme to smuggle over 5,000 unapproved peptides into the U.S.” — Semax named in seized list, operation December 2025 through 25 March 2026.

Retrieval limitations (preserved from Pass 2)

• Direct Reddit thread-level evidence is largely not retrievable via standard search tooling in this pass. r/Nootropics and r/Peptides have well-known heavy historical Semax discussion, but post-2023 Reddit API/indexing changes mean thread titles, dates, vote counts, and permalinks could not be confirmed at named-source resolution.
• The r/Nootropics wiki Semax entry could not be confirmed retrieved.
• Specific Reddit “Semax did nothing for me” placebo-camp threads, the canonical Selank+Semax stack thread, and ADHD-utility threads — none confirmed at thread-title resolution; their existence is inferred via LongeCity coverage and secondary biohacker citation.
• Andrew Huberman has NOT meaningfully discussed Semax on Huberman Lab — this is itself a finding. Peter Attia, Tim Ferriss, Joe Rogan (in his own voice), Layne Norton, and Nathalie Niddam likewise have no dedicated Semax coverage retrievable. Only mainstream-podcast naming is the RFK Jr. JRE #2461 reference in a regulatory list.
• Derek MorePlatesMoreDates — likely covered Semax but no specific MPMD piece could be confirmed by direct citation in this pass.
• Russian-language community sources (Pikabu, VK nootropic communities, Russian Telegram channels) were not surveyed at this pass. Likely contain extensive Semax discourse including direct Peptogen producer interaction.
• Ceretropic-era vendor pages — defunct; Wayback Machine retrieval at per-product detail not completed in this pass.
• UK vendors Mind Nutrition, Cerebral Health, British Brain Bay, Newmind — referenced in LongeCity, not opened at per-product detail.

---

14. Audit / Refresh Trail

• Composed: 17 May 2026
• Pass 1 source: semax_sci_2026-05-17_C15.md; Pass 1 last refresh date 17 May 2026 (prior review 11 May 2026)
• Pass 2 source: semax_com_2026-05-17_B71.md; Pass 2 research date 17 May 2026
• Section 4 Last regulatory review stamp: 2026-05-17 (Pass 1)
• Next refresh triggers:
  • FDA PCAC outcome 24 July 2026 — material regulatory event; refresh within 1 week of vote.
  • FDA notice-and-comment rulemaking outcome post-PCAC (historically 12+ months downstream).
  • Any independent Western or Asian replication of Dolotov 2006 BDNF/TrkB hippocampal finding.
  • Any registered Western Phase 2/3 RCT in cognitive enhancement, stroke, or trigeminal neuralgia.
  • Cochrane SR initiation or publication.
  • Russian GRLS status change for JSC Peptogen Semax 0.1% or 1%.
  • WADA Prohibited List or Monitoring Program update naming Semax.
  • TGA scheduling decision on Semax specifically.
  • Major retraction of any Russian-network Semax study.
  • Significant Huberman / Attia / Ferriss episode on Semax (would shift Community Tier).